A successful joint collaboration between researchers at the Hebrew university of Jerusalem and the startup company TyrNovo may lead to a potential treatment of brain diseases. The researchers found that TyrNovo's novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan.
If the phrase “A better life through science” hasn’t yet been copyrighted, Yissum, the technology transfer company of Hebrew University, may want to grab it. From medicine to environmental technology to information systems, Hebrew U scientists have developed a wide range of important technologies, and thanks to Yissum, those technologies are now available to help people around the world.
Germany's Merck KGaA (XETRA: MRK) has increased its stake in Qlight Nanotech Ltd. to 50%, after a further investment of several million dollars in the Yissum Technology Transfer Company of the Hebrew University of Jerusalem portfolio company. Qlight will use the investment to expand development of its semiconductor nanoparticle-based technology and to address a broader customer base.
The agreement sets the stage for a collaborative research consortium in fields of mutual interest, including pediatric translational research.
Melodea Ltd. announced today that it has been awarded above 1,000,000 Euro in 3 projects of the European Union Seventh Framework Program (FP7).
Yissum Research Development Company, the tech transfer arm of Hebrew University of Jerusalem, is seeking business partners to help commercialize an eco-friendly water purifier for aquariums.
Yissum, the Hebrew University’s research and development arm, introduces SEER – a novel application for predictive speed dialing for smartphones. It is based on an innovative machine-learning algorithm that utilizes the user’s past behavior and the context of the call to predict the next outgoing call.
Yissum launches smartphone application based on a machine-learning algorithm that predicts the next outgoing call.
Yissum Research Development Company, Hebrew University’s Technology Transfer Arm, and Israeli crop-protection company Makhteshim Agan partnered to develop and market a non-toxic and environmentally-friendly bio-control method for protecting plants based on a yeast isolated from strawberry leaves.
QLight Nanotech, a Jerusalem based start-up backed and partly owned by Merck, opened a new facility in Jerusalem last week to further its development of LED lighting and flat-panel display products using semiconductor nanocrystal materials.
Merck KGaA is moving forward with plans to increase its stake in Jerusalem-based Yissum spin off QLight Nanotech, which develops products for use in displays and energy-efficient light sources.
Makhteshim Agan Industries Ltd. and Yissum Technology Transfer Company of the Hebrew University of Jerusalem will jointly develop and commercialize a novel, non-toxic, and environmentally-friendly bio-control method for protecting a variety of plants, based on a naturally-occurring yeast, Pseudozyma that was isolated from strawberry leaves.
HU Biodesign Innovation Program benefits from the expertise of Jerusalem’s best and brightest in medicine, business, engineering and law.
Yissum's spin off Regenecure presents: BoneCure, a revolutionary artificial membrane that speeds and simplifies bone re-growth in pets, may also be headed for the human market.
Yissum spin off Briefcam featured in Mashable: "Using tech to augment how we watch for and catch terrorists and others who would do us harm before they board an aircraft is a process flush with options — and with challenges"
Prof. Yossi Paltiel and research student Oren Ben-Dor at the Hebrew University of Jerusalem's Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, together with researchers from the Weizmann Institute of Science, have developed a simple magnetization progress that, by eliminating the need for permanent magnets in memory devices, opens the door to many technological applications.
The technology transfer companies of the Hebrew University (Yissum) and the Weizmann Institute of Science (Yeda) are working to promote the realization of this technology, by licensing its use and raising funds for further development and commercialization.
Students in Hebrew University-Hadassah Medical Center program develop "science fiction gadgets".
Biodesign entrepreneurship program is Israel's first medical innovation accelerator
Diabetics must be regularly examined by their ophthalmologist to look for leakage of blood inside the retinas of their eyes, which could result in blindness.
Now the Hebrew University of Jerusalem’s technology transfer arm, Yissum Research Development Company, has patented a method for detecting retinal microaneurysms that pose a high risk for leakage. The novel method will enable early diagnosis and treatment of the condition, potentially minimizing damage and saving vision.
Yissum presents exciting technologies at Biomed 2013
This is the largest ever fund raising round by the company, which develops camera-based advanced driver assistance systems for the automotive industry.
